Biotechs and investors are increasingly altering their strategies amid changes in the development and commercial landscape.
Proceeds will go towards a pivotal trial of the candidate in paediatric patients.
Under the agreement, Modalis will be granted rights to utilise EMC181 in the development of MDL-201.
The site will produce bioprocess equipment and consumables used in developing biologics and vaccines.
Thoracic oncologists previously touted Hyrnuo’s potential in HER2-mutant NSCLC in both the first- and second-line settings.
The healthcare team dive into the latest data and emerging trends from the ESC Congress and ERS Congress.
